Merck, Bionomics team up to develop chronic pain drug

Bionomics and Merck & Co. agreed to collaborate in the discovery and development of novel small molecule candidates for treatment of neuropathic pain and other forms of chronic pain using the latter's ionX drug discovery technology and MultiCore chemistry. The deal grants Merck an option for an exclusive license for one compound. Bionomics could get as much as $172 million in option exercise fees and milestone payments plus sales royalties.

View Full Article in:

Genetic Engineering & Biotechnology News · Wall Street Journal (tiered subscription model), The

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
PacificSource
Bend, OR
Clinical Appeals RN
MJHS
Brooklyn, NY
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ